 | The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering
www.benzinga.com - May 31 at 8:23 AM |
 | Merrimack axes remaining staff, execs after selling assets to New York startup
www.bizjournals.com - May 31 at 8:23 AM |
 | Merrimack -2.6% as it decides against sale
seekingalpha.com - May 30 at 6:42 PM |
 | Merrimack Pharmaceuticals Announces Completion of Strategic Review, Preservation of Ipsen Milestones and Special Cash Dividend
finance.yahoo.com - May 30 at 6:42 PM |
 | Merrimack Reports First Quarter 2019 Financial Results
www.prnewswire.com - May 10 at 7:59 AM |
| COMM 2014-UBS2 Mortgage Trust -- Moody's affirms ten classes of COMM 2014-UBS2
finance.yahoo.com - May 3 at 7:14 PM |
| Merrimack to cut headcount after MM-310 flop
seekingalpha.com - April 30 at 6:52 PM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK
finance.yahoo.com - April 9 at 10:15 PM |
| Merrimack Pharmaceuticals, Inc. (MACK) - Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation
finance.yahoo.com - April 8 at 7:50 PM |
 | Merrimack Discontinues Cancer Study Amidst Layoffs
247wallst.com - April 5 at 7:49 PM |
| TrovaGene leads healthcare gainers; Merrimack Pharmaceuticals and Syros Pharmaceuticals among losers
seekingalpha.com - April 5 at 12:25 PM |
| The Merrimack Pharmaceuticals (NASDAQ:MACK) Share Price Is Down 92% So Some Shareholders Are Rather Upset
finance.yahoo.com - April 5 at 10:42 AM |
| Merrimack bails on lead candidate; shares down 9% after hours
seekingalpha.com - April 4 at 8:04 PM |
| Merrimack Discontinues Development of MM-310
finance.yahoo.com - April 4 at 8:04 PM |
| Merrimack shelves another cancer drug, plans more layoffs
finance.yahoo.com - April 4 at 8:04 PM |
 | Merrimack Pharmaceuticals, Inc. Estimate Momentum
www.nasdaq.com - March 20 at 10:47 PM |
| Merrimack Reports Fourth Quarter and Full Year 2018 Financial Results - PRNewswire
www.prnewswire.com - March 7 at 8:33 AM |
| Merrimack Reports Fourth Quarter and Full Year 2018 Financial Results
finance.yahoo.com - March 6 at 8:27 AM |
| John M. Dineen Appointed to Syneos Health Board of Directors, Named Chairman - Nasdaq
www.nasdaq.com - December 10 at 5:29 PM |
| John M. Dineen Appointed to Syneos Health Board of Directors, Named Chairman
finance.yahoo.com - December 10 at 5:29 PM |
 | Merrimack (MACK) Down 7.5% Since Last Earnings Report: Can It Rebound?
www.zacks.com - December 7 at 5:41 PM |
| Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3
finance.yahoo.com - November 9 at 5:35 PM |
| Merrimack to shelve lead cancer drug, lay off most of workforce
finance.yahoo.com - November 8 at 5:38 PM |
| Edited Transcript of MACK earnings conference call or presentation 7-Nov-18 1:30pm GMT
finance.yahoo.com - November 8 at 8:21 AM |
| Merrimack Pharmaceuticals (MACK) CEO Richard Peters on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 7 at 5:47 PM |
| Merrimack Reports Third Quarter 2018 Financial Results and Provides Strategic Update Following Portfolio Review
finance.yahoo.com - November 7 at 8:19 AM |
| Merrimack Pharmaceuticals Q3 Earnings Preview
finance.yahoo.com - November 6 at 5:33 PM |
| Merrimack Announces Timing of Third Quarter 2018 Investor Conference Call
finance.yahoo.com - October 31 at 5:29 PM |
| Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod
www.zacks.com - October 24 at 5:07 PM |
| Merrimack Fails Mid-Stage Study, But 2 Shots On Goal May Help It Redeem Itself
seekingalpha.com - October 22 at 5:21 PM |
 | Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility
www.marketwatch.com - October 20 at 8:19 AM |
 | Merrimack Pharmaceuticals (MACK) PT Lowered to $4 at Baird as MM-121 Disappoints
www.streetinsider.com - October 20 at 8:19 AM |
| Merrimack discontinues Phase 2 study of MM-121 in patients with NSCLC due to futility
seekingalpha.com - October 20 at 8:19 AM |
| Why Merrimack Pharma Is Terminating Its Midstage Lung Cancer Study
247wallst.com - October 20 at 8:19 AM |
| US STOCKS ON THE MOVE-AmEx, AIG, P&G, PayPal, Skechers, Apple, Tesla
www.nasdaq.com - October 19 at 5:10 PM |
| Mid-Morning Market Update: Markets Open Higher; Procter & Gamble Profit Tops Estimates
www.nasdaq.com - October 19 at 5:10 PM |
| Merrimack's String of Failures Continues With Lung Cancer Study Shelved After Midstage Trials
feeds.benzinga.com - October 19 at 12:16 PM |
| Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to ...
www.prnewswire.com - October 19 at 8:25 AM |
| Merrimack Pharmaceuticals' stock plummets toward record low after cancer drug trial terminated
www.marketwatch.com - October 19 at 8:25 AM |
| Detailed Research: Economic Perspectives on Clearside Biomedical, JELD-WEN Holding, L.B. Foster, Merrimack Pharmaceuticals, Everi, and Drive Shack — What Drives Growth in Today's Competitive Landscape
finance.yahoo.com - October 16 at 8:24 AM |
| Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts
www.zacks.com - October 11 at 4:51 PM |
| Global Next-Generation Antibody Therapies Market Forecast 2018-2028 - Visiongain Report
www.prnewswire.com - October 2 at 4:51 PM |
| Merrimack Pharma (MACK) Receives $5M Milestone Payment from Shire
www.streetinsider.com - September 20 at 4:55 PM |
| Merrimack receives $5M milestone payment from Shire
seekingalpha.com - September 20 at 4:55 PM |
| Merrimack Receives $5 Million Milestone Payment from Shire
finance.yahoo.com - September 20 at 8:21 AM |
| Merrimack Pharmaceuticals (MACK) Presents at Baird's Global Healthcare Conference - Slideshow
seekingalpha.com - September 7 at 5:06 PM |
| Merrimack Pharma completes enrollment in mid-stage study of MM-121 in certain type of lung cancer; shares down 2%
seekingalpha.com - September 6 at 5:03 PM |
| Merrimack (MACK) Up 6.7% Since Last Earnings Report: Can It Continue?
finance.yahoo.com - September 6 at 5:03 PM |
| Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC)
finance.yahoo.com - September 6 at 8:25 AM |
| Edited Transcript of MACK earnings conference call or presentation 7-Aug-18 12:30pm GMT
finance.yahoo.com - August 16 at 5:29 PM |
